Cancer treatments

2020 Insights into Head and Neck Cancer Disease Industry - Coverage Forecast and Market Analysis to 2024 - ResearchAndMarkets.com

Friday, July 3, 2020 - 11:23am

The majority of HNC diagnoses (75.2%) worldwide are in males, ranging from 64.9% to 76.3% across regions.

Key Points: 
  • The majority of HNC diagnoses (75.2%) worldwide are in males, ranging from 64.9% to 76.3% across regions.
  • Though a heterogenous group of diseases, the overwhelming majority (90%) of HNCs are comprised of squamous cell carcinomas of the head and neck (HNSCCs).
  • As such, there has been much interest in the development of immunotherapies to allow for a more targeted treatment program.
  • The first immunotherapies approved for recurrent/metastatic HNSCCs are the checkpoint inhibitors Keytruda (for first and second line) and Opdivo (second line only).

Immunomedics to Host Conference Call and Webcast on July 6, 2020 to Provide Clinical Update

Thursday, July 2, 2020 - 9:05pm

To access the conference call, please dial (877) 303-2523 or (253) 237-1755 using the Conference ID 8872919.

Key Points: 
  • To access the conference call, please dial (877) 303-2523 or (253) 237-1755 using the Conference ID 8872919.
  • The conference call will be webcast via the Investors page on the Companys website at https://immunomedics.com/investors/ .
  • Approximately two hours following the live event, a webcast replay of the conference call will be available on the Companys website for approximately 30 days.
  • Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.

The Global Breast Cancer Drugs Market is expected to grow from USD 15,188.90 Million in 2019 to USD 25,364.27 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 8.92%

Thursday, July 2, 2020 - 4:10pm

On the basis of Geography, the Breast Cancer Drugs Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.

Key Points: 
  • On the basis of Geography, the Breast Cancer Drugs Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Breast Cancer Drugs Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breast Cancer Drugs Market?
  • What are the modes and strategic moves considered suitable for entering the Global Breast Cancer Drugs Market?

Global Small Molecule Cancer Drug Market to 2026 - Drug Price, Dosage & Clinical Trials Insight - ResearchAndMarkets.com

Thursday, July 2, 2020 - 10:23am

The "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • The basic targeting advantage along with the dominance of small molecule drugs in cancer clinical pipeline will drive the global small molecule cancer drug market in coming years.
  • Small Molecule Cancer Drug Market Opportunity: More Than US$ 125 Billion by 2026
    USA Dominates The Global Small Molecule Cancer Drug Market: >50% Share
    Small Molecule Cancer Drug Market Clinical Trials: >2500 Drugs
    Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs
    Clinical Trials Insight by Phase, Company, Country, Formulation, Indication
    An important parameter that should be associated with any of the cancer treatment is its specificity.
  • 3.2 Small Molecule Cancer Drug vs. Immunotherapy
    3.3 Small Molecule Cancer Drugs vs.

Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin Prize

Wednesday, July 1, 2020 - 1:30pm

Ton has played a crucial role in understanding how the immune system responds to tumors and translated his scientific discoveries into potential treatments for cancer.

Key Points: 
  • Ton has played a crucial role in understanding how the immune system responds to tumors and translated his scientific discoveries into potential treatments for cancer.
  • We are proud to have him lead our Scientific Advisory Board, where he provides strategic and scientific advice to Allogene as we continue to innovate in allogeneic cell therapy and advance the clinical development of our investigational AlloCAR T therapies.
  • Allogene Therapeutics, with headquarters inSouth San Francisco, is a clinical-stagebiotechnology company pioneering the development of allogeneic chimeric antigen receptor Tcell (AlloCAR T) therapies for cancer.
  • Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA

Tuesday, June 30, 2020 - 9:01pm

Omburtamab is an investigational, monoclonal antibody that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.

Key Points: 
  • Omburtamab is an investigational, monoclonal antibody that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.
  • The omburtamab BLA is for the treatment of pediatric patients with CNS/leptomeningeal metastases from neuroblastoma.
  • We are very grateful to all clinical sites involved in developing omburtamab, and especially to our employees in the development team.
  • Dr. Claus Moller, Chief Executive Officer, continued, We look forward to working with the Agency to bring omburtamab to appropriate patients.

CEL-SCI Corporation Receives $10 Million Through Warrant Exercises

Tuesday, June 30, 2020 - 1:30pm

CEL-SCI Corporation (NYSE American: CVM) announced today that, during the quarter ending June 30, 2020 it has received approximately $10 million from the exercise of warrants.

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) announced today that, during the quarter ending June 30, 2020 it has received approximately $10 million from the exercise of warrants.
  • These funds will allow the Company to complete the expansion of its Multikine* (Leukocyte Interleukin, Inj.)
  • cancer immunotherapy manufacturing facility near Baltimore, MD in anticipation of BLA submission and subsequent marketing approval.
  • CEL-SCI believes that boosting a patients immune system while it is still intact should provide the greatest possible impact on survival.

First Patient Infused in Joint Humanigen/Kite, A Gilead Company Clinical Study

Tuesday, June 30, 2020 - 12:00pm

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.

Key Points: 
  • Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.
  • We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
  • In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.
  • Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration.

Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval of Melflufen in Triple-class Refractory Multiple Myeloma Patients

Tuesday, June 30, 2020 - 7:36am

"I am very proud and humbled by the organizations ability to timely submit the NDA for accelerated approval of melflufen.

Key Points: 
  • "I am very proud and humbled by the organizations ability to timely submit the NDA for accelerated approval of melflufen.
  • In total 157 multiple myeloma patients have been enrolled and evaluated in the pivotal phase 2 HORIZON study.
  • The patients in the study were refractory to pomalidomide and/or daratumumab after failing on immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs).
  • The HORIZON study population includes subgroups of patients who were triple-class refractory and/or had extramedullary disease and/or had cytogenetic high-risk features.

Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval of Melflufen in Triple-class Refractory Multiple Myeloma Patients

Tuesday, June 30, 2020 - 7:32am

"I am very proud and humbled by the organizations ability to timely submit the NDA for accelerated approval of melflufen.

Key Points: 
  • "I am very proud and humbled by the organizations ability to timely submit the NDA for accelerated approval of melflufen.
  • In total 157 multiple myeloma patients have been enrolled and evaluated in the pivotal phase 2 HORIZON study.
  • The patients in the study were refractory to pomalidomide and/or daratumumab after failing on immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs).
  • The HORIZON study population includes subgroups of patients who were triple-class refractory and/or had extramedullary disease and/or had cytogenetic high-risk features.